A new experimental drug called VX093L reduced a liver enzyme called DGAT2 by more than 80% in mice with fatty liver disease, leading to significant decreases in liver fat and scarring. According to Gram Research analysis, the lower dose of VX093L worked better at reducing scarring than resmetirom, an already-approved drug for this condition. While these results are promising, the treatment has only been tested in mice and would require human clinical trials before becoming available to patients.
Researchers have developed a new treatment called VX093L that targets a specific enzyme in the liver responsible for storing fat. In a study using mice fed a high-fat diet, this experimental drug reduced liver fat buildup by over 80% and also decreased liver scarring, a serious complication of fatty liver disease. The treatment worked better than an existing approved drug at reducing scarring without causing inflammation. While these results are promising, the research was conducted in mice, so human testing will be needed before this treatment becomes available to patients.
Key Statistics
A 2026 research study found that VX093L reduced the DGAT2 enzyme in mouse livers by more than 80% after eight weeks of treatment, resulting in significant reductions in both liver fat accumulation and liver scarring.
In mice with high-fat diet-induced fatty liver disease, the lower dose of VX093L (1 mg/kg given twice weekly) demonstrated better anti-scarring effectiveness compared to resmetirom, an approved drug for this condition, without causing increased inflammation.
According to a 2026 study in the Journal of Drug Targeting, VX093L successfully inhibited hepatic triglyceride synthesis in mice, translating improved steatosis into effective attenuation of liver fibrosis.
The Quick Take
- What they studied: Whether a new drug called VX093L could reduce fat buildup and scarring in livers of mice with fatty liver disease caused by eating a high-fat diet
- Who participated: Laboratory mice that were fed a high-fat diet to develop metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease similar to what humans can develop
- Key finding: According to Gram Research analysis, VX093L reduced the enzyme DGAT2 in mouse livers by more than 80%, which led to significant reductions in liver fat and scarring. The lower dose of VX093L (1 mg/kg) actually worked better at reducing scarring than resmetirom, an already-approved drug for this condition.
- What it means for you: This research suggests a potential new treatment pathway for fatty liver disease, but it’s important to note this was tested only in mice. Human clinical trials would be needed before doctors could prescribe this treatment to patients. People with fatty liver disease should continue following their doctor’s current recommendations while researchers work toward human testing.
The Research Details
Scientists designed small pieces of genetic material called siRNAs that target a specific enzyme called DGAT2, which plays a key role in how the liver stores fat. They tested different versions of these genetic tools in liver cells grown in the laboratory to find the most effective one. The best candidate, called VX093L, was then attached to a molecule that helps it reach liver cells specifically. The researchers then tested VX093L in mice that had been fed a high-fat diet to develop fatty liver disease similar to what humans experience. Mice received either VX093L at two different doses or resmetirom, an existing approved drug, over an eight-week period. The scientists measured how much the drug reduced the DGAT2 enzyme, how much liver fat decreased, and whether liver scarring improved.
This research approach is important because it tests a completely new type of treatment strategy. Rather than using a traditional chemical drug, this treatment uses genetic material to turn off the production of a specific enzyme. This targeted approach may reduce side effects because it only affects the liver and specifically targets one enzyme involved in fat storage. Testing in mice first allows researchers to understand how the drug works and whether it’s safe before attempting human trials.
This is laboratory and animal research, which is an important early step in drug development but has limitations. The study was conducted in mice, not humans, so results may not directly translate to people. The research appears to be well-designed with appropriate controls and measurements, but the sample size of mice is not specified in the available information. The journal, Journal of Drug Targeting, is a respected publication in pharmaceutical research. Because this is early-stage research, much more testing would be needed before this treatment could be used in patients.
What the Results Show
The experimental drug VX093L successfully reduced the DGAT2 enzyme in mouse livers by more than 80% after eight weeks of treatment. This reduction in the enzyme led to a significant decrease in how much fat accumulated in the liver, addressing the primary problem in fatty liver disease. Importantly, the improvement in liver fat also resulted in reduced liver scarring, which is a serious complication that can eventually lead to liver failure. The lower dose of VX093L (1 mg/kg given twice per week) was actually more effective at reducing scarring than resmetirom, a drug that is already approved and used to treat this condition in humans. This is significant because it suggests the new treatment might work better than current options. The benefits occurred without causing increased inflammation in the liver, which is important because inflammation can worsen liver disease.
The research also showed that VX093L was effective at reducing triglycerides, which are a type of fat that accumulates in the liver. The drug worked consistently across different dose levels tested. The treatment appeared to be well-tolerated in the mice, with no signs of serious side effects reported. The sustained effect of the drug in the liver suggests it could potentially be given less frequently than some other treatments, which could make it more convenient for patients if it proves effective in humans.
This research builds on previous understanding that DGAT2 is an important target for treating fatty liver disease. The use of siRNA technology represents a newer approach compared to traditional chemical drugs like resmetirom. While resmetirom works through a different mechanism, VX093L appears to offer comparable or better results at reducing scarring. This suggests that targeting DGAT2 specifically may be a valuable addition to the treatment options available for this disease. The research supports the idea that multiple different approaches to treating fatty liver disease may be needed, as different patients may respond better to different treatments.
This study was conducted entirely in mice, not humans, so the results may not directly apply to people. Mice metabolize drugs differently than humans do, and they don’t experience all the same complications that humans with fatty liver disease face. The exact number of mice used in the study was not specified in the available information. The study only lasted eight weeks, so it’s unclear whether the benefits would continue long-term or whether tolerance to the drug might develop over time. The research doesn’t include information about potential side effects in humans or how the drug might interact with other medications. Before this treatment could be used in patients, it would need to go through multiple phases of human clinical trials to confirm safety and effectiveness.
The Bottom Line
This research is too early-stage to make recommendations for patient use. The findings suggest VX093L is a promising candidate for future development, but it remains an experimental treatment. People currently dealing with fatty liver disease should continue working with their healthcare providers and following evidence-based recommendations such as weight loss, reducing sugar and fat intake, and regular exercise. If this drug advances to human trials, eligible patients may have the opportunity to participate and help determine whether these promising mouse results translate to real benefits for people.
This research is most relevant to people with metabolic dysfunction-associated steatohepatitis (MASH), previously called nonalcoholic fatty liver disease (NAFLD). It’s also important for researchers and pharmaceutical companies developing new treatments for liver disease. Healthcare providers who treat liver disease should be aware of this emerging treatment approach. People with risk factors for fatty liver disease, such as obesity or type 2 diabetes, may find this research encouraging as it represents progress toward new treatment options. However, this research should not change anyone’s current treatment plan, as the drug is not yet available for human use.
If this drug follows a typical development path, human clinical trials could begin within the next few years, but approval for patient use would likely take five to ten years or more. Early human trials would first focus on safety and finding the right dose. Later trials would measure whether the drug actually improves liver health in patients. Even if human trials are successful, regulatory approval would be required before the drug could be prescribed. People with fatty liver disease should not expect this treatment to become available soon, but this research represents meaningful progress toward new options.
Frequently Asked Questions
What is DGAT2 and why is it important for treating fatty liver disease?
DGAT2 is an enzyme that helps the liver store fat by creating triglycerides. By reducing this enzyme, VX093L decreases fat accumulation in the liver. In the 2026 mouse study, blocking DGAT2 by over 80% significantly reduced both liver fat and scarring, making it a promising therapeutic target.
How does VX093L compare to existing fatty liver disease treatments?
VX093L outperformed resmetirom, an approved drug, at reducing liver scarring in mice. The lower dose of VX093L (1 mg/kg) was more effective than the standard dose of resmetirom (10 mg/kg daily) without causing inflammation, suggesting it may offer advantages over current treatment options.
When will VX093L be available for patients with fatty liver disease?
VX093L is still in early research stages, tested only in mice. Human clinical trials would need to occur before regulatory approval, a process typically taking five to ten years or longer. People with fatty liver disease should continue current evidence-based treatments while this drug undergoes development.
What should I do now if I have fatty liver disease?
Continue working with your healthcare provider on proven strategies: lose weight if overweight, reduce sugar and saturated fat intake, exercise regularly, and limit alcohol. These lifestyle changes remain the most effective current treatments. Stay informed about emerging therapies like VX093L through your doctor.
Why was this drug tested in mice instead of humans?
Animal testing is a required early step in drug development to evaluate safety and effectiveness before human trials. Mice develop similar fatty liver disease to humans and allow researchers to test whether VX093L works as intended. Successful mouse studies support moving toward human clinical trials.
Want to Apply This Research?
- Users interested in fatty liver disease management could track weekly measurements of waist circumference and daily food intake, specifically monitoring grams of added sugar and saturated fat consumed, to measure progress on evidence-based lifestyle interventions while awaiting new treatment options.
- Users could set a goal to reduce daily added sugar intake by 25 grams per week and increase weekly aerobic exercise by 30 minutes, logging these activities in the app to build sustainable habits that help manage fatty liver disease risk factors.
- Establish a monthly check-in system where users record their weight, exercise frequency, and dietary adherence. Users should also note any medical appointments or new information about emerging treatments like VX093L, creating a personal health timeline to discuss with their healthcare provider.
This article describes early-stage research conducted in mice and does not represent medical advice. VX093L is an experimental drug not yet approved for human use. People with fatty liver disease should consult their healthcare provider about current treatment options and should not delay or change their current medical care based on this research. This information is for educational purposes only and should not be used to diagnose, treat, or prevent any disease. Always speak with a qualified healthcare professional before making changes to your health regimen.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.